Mustafa, Mohamad and Mohamed, Mohamed B. and Hayat, Amjad (2017) Tumour Lysis Syndrome and Partial Remission Occurring After Administration of a Test Dose of Obinutuzumab. European Journal of Case Reports in Internal Medicine, 4 (1). ISSN 2284-2594
|
Text
Paper 2.pdf - Published Version Download (236kB) | Preview |
Abstract
Chronic lymphocytic leukaemia (CLL) is one of the most common haematological malignancies worldwide, with an increasing prevalence in the elderly population. Obinutuzumab is a type II anti-CD20 monoclonal antibody which showed superiority over rituximab in combination chemotherapy with chlorambucil for the treatment of CLL in the CLL11 trial (NCT01010061) and is becoming part of standard first line treatment for CLL in the elderly based on its potent efficacy and benign safety profile. We report the case of a chemotherapy naive patient who develop tumour lysis syndrome despite appropriate prophylaxis, and had partial remission of her disease after receiving only the initial test dose of obinutuzumab.
| Item Type: | Article |
|---|---|
| Uncontrolled Keywords: | Chronic lymphocytic leukaemia; Obinutuzumab; tumour lysis syndrome |
| Subjects: | 600 Tecnologia - Scienze applicate > 610 Medicina e salute (Classificare qui la tecnologia dei servizi medici) > 616 Malattie (classificare qui la Clinica medica, la medicina basata sull'evidenza, la Medicina interna, la Medicina sperimentale) |
| Depositing User: | Chiara D'Arpa |
| Date Deposited: | 27 Feb 2017 17:33 |
| Last Modified: | 27 Feb 2017 17:33 |
| URI: | http://eprints.bice.rm.cnr.it/id/eprint/16045 |
Actions (login required)
 |
View Item |
